📊 IVF Key Takeaways
Is INVO Fertility, Inc. (IVF) a Good Investment?
INVO Fertility is in financial distress with a severely negative cash burn of $1.9M annually against only $2.0M in revenue, resulting in a $5.5M net loss. The company faces acute liquidity challenges with a 0.90x current ratio and only $4.9M cash available, suggesting a sub-3-quarter runway at current burn rates. Absent significant operational improvements or capital infusion, the company risks insolvency.
Fundamentals are severely weak: modest 4.7% revenue growth is accompanied by a 13.7% gross margin, deeply negative operating and net margins, and free cash flow nearly equal to revenue. Positive equity, $4.90 million of cash, and low long-term debt provide some balance-sheet support, but sub-1.0 liquidity ratios and continued cash burn create substantial financing and dilution risk.
INVO Fertility, Inc. Key Strengths (IVF)
- Low leverage with debt-to-equity of 0.04x provides financial flexibility for potential restructuring
- Modest revenue growth of 4.7% YoY shows some market traction despite operational challenges
- Improved EPS trend (+94.3% YoY) indicates loss reduction trajectory, though still deeply negative
- Revenue increased 4.7% year over year
- Low long-term debt of $660,160 and debt-to-equity of 0.04x
- Positive stockholders' equity of $15.02 million
IVF Stock Risks: INVO Fertility, Inc. Investment Risks
- Severe liquidity crisis with current ratio of 0.90x and negative operating cash flow of -$1.9M threatens solvency within 2-3 quarters
- Extremely low gross margin of 13.7% indicates fundamental business model or manufacturing cost issues not being resolved
- No insider buying activity and continued massive losses suggest management lacks confidence in near-term turnaround
- Net loss of $5.54 million substantially exceeds quarterly revenue
- Free cash flow was negative $1.96 million with a -97.3% margin
- Current ratio of 0.90x indicates inadequate short-term liquidity
Key Metrics to Watch
- Monthly operating cash burn rate relative to remaining cash runway
- Gross margin trend and ability to reduce cost of goods sold through operational improvements
- Revenue growth acceleration and path to positive unit economics
- Operating cash burn and remaining cash runway
- Gross margin and operating margin progression
INVO Fertility, Inc. (IVF) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
IVF Profit Margin, ROE & Profitability Analysis
IVF vs Healthcare Sector: How INVO Fertility, Inc. Compares
How INVO Fertility, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is INVO Fertility, Inc. Stock Overvalued? IVF Valuation Analysis 2026
Based on fundamental analysis, INVO Fertility, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
INVO Fertility, Inc. Balance Sheet: IVF Debt, Cash & Liquidity
IVF Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: INVO Fertility, Inc.'s revenue has grown significantly by 58% over the 5-year period, indicating strong business expansion. The most recent EPS of $-3,782.65 indicates the company is currently unprofitable.
IVF Revenue Growth, EPS Growth & YoY Performance
IVF Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2025 | $1.6M | -$1.6M | $-7.55 |
| Q3 2024 | $974.9K | -$1.2M | $-0.42 |
| Q2 2024 | $315.9K | -$1.6M | $-0.62 |
| Q1 2024 | $348.0K | -$1.6M | $-0.42 |
| Q3 2023 | $235.3K | -$1.2M | $-0.70 |
| Q2 2023 | $146.1K | -$2.2M | $-3.06 |
| Q1 2023 | $162.6K | -$2.6M | $-0.20 |
| Q3 2022 | $218.9K | -$2.2M | $-0.21 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
INVO Fertility, Inc. Dividends, Buybacks & Capital Allocation
IVF SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for INVO Fertility, Inc. (CIK: 0001417926)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IVF
What is the AI rating for IVF?
INVO Fertility, Inc. (IVF) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 91% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are IVF's key strengths?
Claude: Low leverage with debt-to-equity of 0.04x provides financial flexibility for potential restructuring. Modest revenue growth of 4.7% YoY shows some market traction despite operational challenges. ChatGPT: Revenue increased 4.7% year over year. Low long-term debt of $660,160 and debt-to-equity of 0.04x.
What are the risks of investing in IVF?
Claude: Severe liquidity crisis with current ratio of 0.90x and negative operating cash flow of -$1.9M threatens solvency within 2-3 quarters. Extremely low gross margin of 13.7% indicates fundamental business model or manufacturing cost issues not being resolved. ChatGPT: Net loss of $5.54 million substantially exceeds quarterly revenue. Free cash flow was negative $1.96 million with a -97.3% margin.
What is IVF's revenue and growth?
INVO Fertility, Inc. reported revenue of $2.0M.
Does IVF pay dividends?
INVO Fertility, Inc. does not currently pay dividends.
Where can I find IVF SEC filings?
Official SEC filings for INVO Fertility, Inc. (CIK: 0001417926) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IVF's EPS?
INVO Fertility, Inc. has a diluted EPS of $-3.38.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is IVF's fundamental grade?
Based on our AI fundamental analysis in August 2026, INVO Fertility, Inc. has a D grade with 91% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is IVF stock overvalued or undervalued?
Valuation metrics for IVF: ROE of -36.9% (sector avg: 15%), net margin of -274.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is IVF's AI grade for 2026?
Our dual AI analysis gives INVO Fertility, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IVF's free cash flow?
INVO Fertility, Inc.'s operating cash flow is $-1.9M, with capital expenditures of $43.4K. FCF margin is -97.3%.
How does IVF compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -274.9% (avg: 12%), ROE -36.9% (avg: 15%), current ratio 0.90 (avg: 2).